REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the Month of July, 2023
Commission File Number: 001-12033
Nymox Pharmaceutical Corporation
(Translation of registrant’s name into English)
Bay & Deveaux Streets, Nassau, The Bahamas
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
On July 13, 2023, Nymox Pharmaceutical Corporation (the “Company”) issued a press release providing additional information concerning recent changes in the Company’s board of directors and management, as well as additional information regarding the Company’s conclusion that a potential transaction was not in the best interests of the Company and its shareholders. This press release is furnished as Exhibit 99.1 to this report on Form 6-K and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Act”), or otherwise subject to the liabilities of that section.
On July 18, 2023, the Company issued a press release announcing the issuances of several of its important U.S. patents for NYMOZARFEX™. This press release is furnished as Exhibit 99.2 to this report on Form 6-K and shall not be deemed to be “filed” for the purposes of Section 18 of the Act, or otherwise subject to the liabilities of that section.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: July 25, 2023
NYMOX PHARMACEUTICAL CORPORATION
By:
/s/ Paul Averback
Name:
Paul Averback
Title:
President and Chief Executive Officer
3
We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.
